250
Participants
Start Date
May 11, 2022
Primary Completion Date
October 26, 2023
Study Completion Date
November 14, 2023
ATI-1777 2.0% w/w
ATI-1777 topical solution 2.0% w/w
ATI-1777 1.0% w/w
ATI-1777 topical solution 1.0% w/w
ATI-1777 0.5% w/w
ATI-1777 topical solution 0.5% w/w
Vehicle
Vehicle topical solution
Aclaris Investigational Site, Richmond
Aclaris Investigational Site, Wilmington
Aclaris Investigational Site, Greenville
Aclaris Investigational Site, Sandy Springs
Aclaris Investigational Site, Miami Lakes
Aclaris Investigational Site, Miami
Aclaris Investigational Site, West Palm Beach
Aclaris Investigational Site, Delray Beach
Aclaris Investigational Site, Tampa
Aclaris Investigational Site, Birmingham
Aclaris Investigational Site, Murfreesboro
Aclaris Investigational Site, Indianapolis
Aclaris Investigational Site, New Albany
Aclaris Investigational Site, West Lafayette
Aclaris Investigational Site, Skokie
Aclaris Investigational Site, Normal
Aclaris Investigational Site, Saint Joseph
Aclaris Investigational Site, Houma
Aclaris Investigational Site, Baton Rouge
Aclaris Investigational Site, Bryant
Aclaris Investigational Site, North Little Rock
Aclaris Investigational Site, Oklahoma City
Aclaris Investigational Site, Dallas
Aclaris Investigational Site, Arlington
Aclaris Investigational Site, Houston
Aclaris Investigational Site, San Antonio
Aclaris Investigational Site, Castle Rock
Aclaris Investigational Site, Colorado Springs
Aclaris Investigational Site, Scottsdale
Aclaris Investigational Site, Encino
Aclaris Investigational Site, Encinitas
Aclaris Investigational Site, Medford
Lead Sponsor
Aclaris Therapeutics, Inc.
INDUSTRY